BC Week In Review | Mar 10, 2014
Clinical News

Aimspro regulatory update

Daval said FDA granted Orphan Drug designation to Aimspro to treat systemic sclerosis. The anti-inflammatory agent derived from hyperimmune caprine serum has completed a Phase II trial to treat late-stage diffuse cutaneous systemic sclerosis. It...
BC Week In Review | Oct 31, 2011
Clinical News

Aimspro: Phase IIa data

A double-blind, placebo-controlled Phase IIa trial in 20 patients with diffuse systemic sclerosis showed that twice-weekly 4.5 mg/mL subcutaneous Aimspro for 26 weeks was well tolerated with no deterioration in hematological, biochemical, immunologic, cardiologic or...
BC Week In Review | Jun 8, 2009
Clinical News

Aimspro regulatory update

Daval said the Australian Therapeutic Goods Administration (TGA) granted Orphan Drug designation for Aimspro to treat amyotrophic lateral sclerosis (ALS). The anti-inflammatory agent derived from hyperimmune caprine serum, which already has Orphan designation in Australia...
Items per page:
1 - 3 of 3